European regulators offer positive opinion on AstraZeneca drug that treats kidney, heart failure conditions


AstraZeneca announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency has issued a positive opinion recommending the approval of ZS-9 for the treatment of hyperkalaemia.

The serious condition is characterized by high potassium levels in the blood serum caused by cardiovascular and kidney diseases.

Results from a late phase study showed that in patients with hyperkalaemia, using the medicine significantly reduced blood serum potassium to normal levels within 48 hours, with levels maintained during 12 days of maintenance therapy.

The condition occurs in 23 to 47 percent of patients with chronic kidney disease and chronic heart failure, both key strategic areas of focus for AstraZeneca.


The opinion will now be advanced to the European Commission (EC) for adoption of a decision on EU-wide marketing authorization of the medicine. The final decision will be applicable to all 28 European Union member countries plus Iceland, Norway and Liechtenstein.

Sodium zirconium cyclosilicate is being developed by ZS Pharma, a subsidiary of AstraZeneca. It is currently also under regulatory review in Australia and by the FDA in the US, with decisions expected in the first half of 2017.

AstraZeneca employs 1,500 people in Delaware.

Facebook Comments
Previous articleUpdated: DuPont stock price near two-decade high on positive merger reports
Next articleM Cubed ceramics seeks $1.24 million financial package from state
Delaware Business Now is a four-year-old, five-day-a-week newsletter and website operated by Bird Street Media LLC. Publisher and Chief Content Officer is Doug Rainey, a 30-year veteran of business journalism in the state of Delaware.  Business Now focuses on breaking business news in Delaware and immediate adjacent areas with apropriate background and perspective. Also offered exclusively in our FREE newsletter is commentary on state and regional issues. Have a complaint, question or even a compliment? Send an email to For advertising information, click on the About tab at the top of the home page Our business hours are 8 a.m. to 5 p.m., Monday through Friday. Call us at 302.753.0691.